Glimepiride therapy for type 2 diabetes mellitus: A systematic review

Chinese Journal of Evidence-Based Medicine

Volumn 9, Issue 10, 2009, Pages 1094-1098

  Liu, Ru Ming ^a,b   Jia, Ping ^c   Tang, Yao ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c Department of Pharmacy   (China)

Author keywords

Adverse drug reactions; Glimepiride; RCT; Systematic review; Type 2 diabetes mellitus

Indexed keywords

GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

CLINICAL TRIAL; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 74249099248     PISSN: 16722531     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. International Diabetes Federation. Diabetes Atlas (third edition). 2007.
2. 2006, 787.
3. 2008, 4(6): 54-55.
4. 2006, 797.
5. American Diabetes Association: The pharmacological treatment of hyperglycemia in NIDD-M. Diabetes Care, 1995, 18(11): 1510-1518.
6. American Diabetes Association: Guide to diagnosis and classification of diabetes mellitus and other categories of glucose intolerance (Position Statement). Diabetes Care, 1997, 20(Suppl. 1): S21.
7. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of Randomized clinical trials: is blinding necessary? Control Clin Trials, 1996, 17(1): 1-12.
8. Roberts VL, Stewart J, Issa M, et al. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther, 2005, 27(10): 1535-1547.
9. Madsbad S, Schmitz O, Ranstam J, et al. Improved glycemic control with no weight increase in patients with type 2 diabetes after oncedaily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care, 2004, 27(6): 1335-1342.
10. Luis Bautista J, Bugos C, Dirnberger G, et al. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. clinical therapeutics, 2003, 25(1): 194-209.
11. DS Schade, L Jovanovic, J Schneider. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. the journal of Clinical Pharmacology, 1998, 38(7): 636-641.
12. Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Diabetes Care, 1996, 19(11): 1194-1199.
13. Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care, 1996, 19(8): 849-856.
14. Vickers A, Goyal N, Harland R, et al. Do certain countries produce only positNe results? A systematic review of controlled trials. Control Clin Trials, 1998, 19(2): 159-166.